DK1656095T3 - N,n-dihalogengenerede aminosyrer og derivater - Google Patents
N,n-dihalogengenerede aminosyrer og derivater Download PDFInfo
- Publication number
- DK1656095T3 DK1656095T3 DK04801985.5T DK04801985T DK1656095T3 DK 1656095 T3 DK1656095 T3 DK 1656095T3 DK 04801985 T DK04801985 T DK 04801985T DK 1656095 T3 DK1656095 T3 DK 1656095T3
- Authority
- DK
- Denmark
- Prior art keywords
- solution
- composition
- dichloro
- amino acid
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/02—Compounds containing nitrogen-to-halogen bonds
- C07C239/04—N-halogenated amines
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
- A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
- A01N41/04—Sulfonic acids; Derivatives thereof
- A01N41/08—Sulfonic acid halides; alpha-Hydroxy-sulfonic acids; Amino-sulfonic acids; Thiosulfonic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Claims (13)
1. Sammensætning med bakteriedræbende, antibakteriel, infektionshæmmende, antimikrobiel, desinficerende, antifungal, sporedræbende og antiviral aktivitet, der omfatter en N,N-dihalogen-aminosyre udvalgt fra gruppen bestående af N,N-dichlor-2,2-dirmethyltaurin, Ν,Ν-dichlor-1,1,2,2-tetramethyltaurin, N,N-dibrom-2,2-dimethyltaurin, N,N-dibrom-l,l,2,2-tetramethyltaurin, N,N-dichlor-3,3-dimethylhomotaurin eller et derivat deraf; hvilket derivat er udvalgt ffa gruppen bestående af farmaceutisk acceptable salte og estere med Ci-C6-alkanoler.
2. Sammensætning ifølge krav 1, hvor sammensætningen omfatter en farmaceutisk acceptabel bærer.
3. Sammensætning ifølge krav 1, der har et pH-forhold på mellem 2 til 7, eller 3,0 til 6,0, eller 3,0 til 5,0 eller 3,5.
4. Sammensætning ifølge krav 1, hvilken sammensætning er isotonisk og fysiologisk afbalanceret.
5. Sammensætning ifølge krav 1, hvor Ν,Ν-dihalogenaminosyren er udvalgt fra gruppen bestående af N,N-dichlor-2,2-dimethyltaurin, Ν,Ν-dichlor-1,1,2,2-tetramethyltaurin, N,N-dibrom-2,2- dimethyltaurin, N,N-dibrom-l,l,2,2-tetramethyltaurin og N,N-dichlor-3,3-dimethylhomotaurin. 6. Ν,Ν-dihalogenaminosyre udvalgt fra gruppen bestående af N,N-dichlor-2,2-dimethyltaurin, Ν,Ν- dichlor- 1,1,2,2-tetramethyltaurin, N,N-dibrom-2,2-dimethyltaurin, N,N-dibrom-l, 1,2,2- tetramethyltaurin, N,N-dichlor-3,3-dimethylhomotaurin eller et derivat deraf, hvor derivatet er udvalgt fra gruppen bestående af farmaceutisk acceptable salte og estere med Ci-C6-alkanoler. 7. Ν,Ν-dihalogenaminosyre ifølge krav 6, der er N,N-dichlor-2,2-dimethyltaurin; eller et farmaceutisk acceptabelt salt deraf.
8. Sammensætning, der omfatter en Ν,Ν-dihalogenaminosyre ifølge krav 6 eller et derivat deraf, hvilket derivat er udvalgt fra gruppen bestående af farmaceutisk acceptable salte og estere med C1-C6-alkanoler til anvendelse i medicin.
9. Anvendelse af en Ν,Ν-dihalogen-aminosyre ifølge et hvilket som helst af kravene 6 til 8 i fremstillingen af en bakteriedræbende, antibakteriel, infektionshæmmende, antimikrobiel, sporedræbende, desinficerende, antifungal og antiviral aktivitetssammensætning eller i fremstillingen af en medikamentsammensætning til bakteriedræbende, antibakteriel, infektionshæmmende, antimikrobiel, sporedræbende, desinficerende, antifungal og antiviral anvendelse.
10. Fremgangsmåde til desinfektion ved kontrol med eller forebyggelse af væksten af bakterier, mikrober, sporer, fungi eller vira, hvilken fremgangsmåde omfatter påføring af en effektiv mængde af en sammensætning ifølge krav 1 til et område, rum eller materiale, der kræver kontrol eller forebyggelse af vækst eller proliferation, forudsat at fremgangsmåden ikke anvendes som en fremgangsmåde til behandling af menneske- eller dyrekroppen ved terapi.
11. Fremgangsmåde ifølge krav 10, hvor sammensætningens pH er på mellem 2 til 7, 3,0 til 6,8, eller 3,0 til 6,0 eller 3,0 til 5,0 eller 3,5.
12. Fremgangsmåde ifølge krav 10, hvor Ν,Ν-dihalogenaminosyren eller derivatet deraf fremstilles in situ.
13. Fremgangsmåde ifølge krav 10, hvor materialet, der skal behandles, er udvalgt fra fødevarer, dyrefoder, kirurgiske instrumenter, kirurgisk udstyr, medicinske anordninger og udstyr, der anvendes til sådanne formål.
14. Sammensætning ifølge krav 8, der har en koncentration af Ν,Ν-dihalogenaminosyren eller dets derivat på mellem 0,1 og 100 eller 0,3 til 50 mM og et pH-område på mellem 2 til 7, 3 til 4,8, 3,0 til 4,5 eller 3,5 til 4,5 eller 3,5.
15. Sammensætning ifølge krav 8 i stabiliseret form, hvilken sammensætning har en koncentration af Ν,Ν-dihalogenaminosyren eller dets derivat på mellem 0,1 og 100 eller 0,1 til 50 mM og et pH-forhold på mellem 2 til 7, 3 til 6, 3 til 4,8, 3 til 4,5 eller 3,5 til 4,5 eller på 3,5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49620703P | 2003-08-18 | 2003-08-18 | |
| PCT/US2004/026603 WO2005020896A2 (en) | 2003-08-18 | 2004-08-17 | N,n-dihalogenated amino acids and derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1656095T3 true DK1656095T3 (da) | 2014-03-10 |
Family
ID=34272488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04801985.5T DK1656095T3 (da) | 2003-08-18 | 2004-08-17 | N,n-dihalogengenerede aminosyrer og derivater |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7462361B2 (da) |
| EP (2) | EP2725008A1 (da) |
| JP (1) | JP4994033B2 (da) |
| KR (1) | KR101057609B1 (da) |
| CN (1) | CN1902158B (da) |
| AR (1) | AR047757A1 (da) |
| AU (1) | AU2004268546B2 (da) |
| BR (1) | BRPI0413660A (da) |
| CA (1) | CA2535926C (da) |
| DK (1) | DK1656095T3 (da) |
| ES (1) | ES2444845T3 (da) |
| HK (1) | HK1103713A1 (da) |
| IL (1) | IL173726A (da) |
| MX (1) | MXPA06001898A (da) |
| NZ (1) | NZ545654A (da) |
| PL (1) | PL1656095T3 (da) |
| PT (1) | PT1656095E (da) |
| SG (1) | SG149043A1 (da) |
| SI (1) | SI1656095T1 (da) |
| TW (1) | TWI376364B (da) |
| WO (1) | WO2005020896A2 (da) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7393522B2 (en) * | 2000-01-12 | 2008-07-01 | Novabay Pharmaceuticals, Inc. | Physiologically balanced, ionized, acidic solution and methodology for use in wound healing |
| ES2377945T3 (es) | 2001-12-05 | 2012-04-03 | Oculus Innovative Sciences, Inc. | Método y aparato para producir agua con potencial de oxidación y reducción (ORP) negativo y positivo |
| BRPI0413660A (pt) | 2003-08-18 | 2006-10-24 | Novacal Pharmaceuticals Inc | Aminoácidos n,n-di-alogenado e derivados |
| US9168318B2 (en) | 2003-12-30 | 2015-10-27 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and methods of using the same |
| TWI386201B (zh) | 2005-01-25 | 2013-02-21 | Novabay Pharmaceuticals Inc | Ｎ-鹵化胺基酸、ｎ，ｎ-二鹵化胺基酸與其衍生物；以及使用其之組合物與方法 |
| EP1863502B1 (en) | 2005-03-23 | 2018-09-12 | Sonoma Pharmaceuticals, Inc. | Method of treating skin ulcers using oxidative reductive potential water solution |
| US9498548B2 (en) | 2005-05-02 | 2016-11-22 | Oculus Innovative Sciences, Inc. | Method of using oxidative reductive potential water solution in dental applications |
| AU2006302370B2 (en) * | 2005-10-06 | 2012-06-14 | Novabay Pharmaceuticals, Inc. | System and method for the prevention of bacterial and fungal infections including urinary tract infections (UTI) using N-halogenated amino acids |
| US8147444B2 (en) | 2006-01-20 | 2012-04-03 | Oculus Innovative Sciences, Inc. | Methods of treating or preventing peritonitis with oxidative reductive potential water solution |
| US20070292488A1 (en) * | 2006-06-14 | 2007-12-20 | Mansour Bassiri | Method for treatment of wound treatment using aganocides |
| TW200843787A (en) * | 2006-12-29 | 2008-11-16 | Novabay Pharmaceuticals Inc | N-halogenated amino compounds and derivatives; compositions and methods of using them |
| WO2008094663A2 (en) * | 2007-01-31 | 2008-08-07 | Adam Heller | Electrochemical management of pain |
| UY31056A1 (es) * | 2007-05-01 | 2008-10-31 | Alcon Res Ltd | Fromulaciones aminocido n-halogenado y metodos de limpieza y desinfeccion |
| UY31058A1 (es) * | 2007-05-01 | 2008-10-31 | Alcon Res Ltd | Formulaciones de aminoacido n-halogenado con compuestos antiinflamatorios |
| UY31059A1 (es) * | 2007-05-01 | 2008-10-31 | Alcon Res Ltd | Formulaciones de aminoacido n-halogenado |
| UY31057A1 (es) * | 2007-05-01 | 2008-10-31 | Alcon Res Ltd | Formulaciones de aminoacido n-halogenado que contiene acido alifatico |
| US7524512B2 (en) * | 2007-07-13 | 2009-04-28 | Di Bartolomeo Joseph R | Composition and method for the prevention and relief of the symptoms of an incompetent or patulous Eustachian tube |
| UY31055A1 (es) * | 2008-02-01 | 2008-10-31 | Alcon Res Ltd | Sales antimicrobianas de aminoacido n-halogenado |
| US20110151025A1 (en) * | 2008-04-10 | 2011-06-23 | Novabay Pharmaceuticals, Inc. | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections |
| US20110091570A1 (en) * | 2008-04-15 | 2011-04-21 | Waldemar Gottardi | Compositions and Devices for Antisepsis and Anticoagulation |
| KR20110043661A (ko) * | 2008-08-12 | 2011-04-27 | 노바베이 파마슈티칼즈, 인코포레이티드 | 항미생물 젤 제형물 |
| WO2010054009A1 (en) * | 2008-11-07 | 2010-05-14 | Novabay Pharmaceuticals, Inc. | Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions |
| EP2341886B1 (en) | 2008-11-07 | 2015-08-26 | NovaBay Pharmaceuticals, Inc. | Antimicrobial n-chlorinated compositions |
| WO2010091280A1 (en) | 2009-02-06 | 2010-08-12 | Alcon Research, Ltd. | N-halogenated amino acid formulations comprising phosphine or amine oxides |
| AU2010241947B2 (en) * | 2009-03-27 | 2014-01-16 | Gojo Industries, Inc. | Compositions and methods for screening and using compounds antagonizing spore-surface interactions |
| US20100272783A1 (en) * | 2009-04-24 | 2010-10-28 | Novabay Pharmaceuticals, Inc. | Methods of Treating Infections of the Nail |
| CA2765696C (en) | 2009-06-15 | 2018-03-06 | Oculus Innovative Sciences, Inc. | Solution containing hypochlorous acid and methods of using same |
| US20110190392A1 (en) * | 2010-02-04 | 2011-08-04 | Azar Najafi | Polysaccharide Based Antimicrobial Formulations |
| CA2814378A1 (en) | 2010-10-19 | 2012-04-26 | Novabay Pharmaceuticlas, Inc. | Antimicrobial polyether and polyol compounds |
| JPWO2012157699A1 (ja) * | 2011-05-18 | 2014-07-31 | 味の素株式会社 | 動物用免疫賦活剤、それを含む飼料及びその製造方法 |
| EP2720665A2 (en) | 2011-06-15 | 2014-04-23 | Rls Global Ab | Detection and removal of carious dentin tissue. |
| US9028807B2 (en) | 2012-04-05 | 2015-05-12 | Ues, Inc. | Synthesis models for antimicrobial agents via the halogenation of organic/inorganic composites |
| SE536581C2 (sv) | 2012-07-24 | 2014-03-11 | Rls Global Ab | Ett kit för behandling av sår eller liknande och ett preparat och metoder därav |
| MX2018015233A (es) | 2016-06-09 | 2019-05-06 | Johnson Matthey Plc | Produccion electrolitica de soluciones de cloramina organica. |
| MX2020008026A (es) * | 2018-01-30 | 2020-09-10 | Buckman Laboratories Int Inc | Combinaciones sinergicas de monocloramina y acido organico, y metodos de uso de las mismas para control microbiano. |
| CN111116406B (zh) * | 2019-12-31 | 2020-12-25 | 吉林大学 | 一种能在物品表面形成杀菌涂层的卤胺及在物品表面形成杀菌涂层的方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3998945A (en) | 1972-06-12 | 1976-12-21 | National Patent Development Corporation | Dental treatment |
| US3950536A (en) * | 1974-02-01 | 1976-04-13 | Sol Joseph Barer | N,N-Dichloro substituted aminocarboxylic acids as bactericides and fungicides |
| US4015008A (en) * | 1974-02-01 | 1977-03-29 | National Patent Development Corporation | N,N-dichloro substituted aminocarboxylic acids as microbiocides |
| US3966796A (en) | 1974-06-14 | 1976-06-29 | Interx Research Corporation | N-chloro-amino acid derivatives activity |
| US4045578A (en) | 1974-06-14 | 1977-08-30 | Interx Research Corporation | N-chloro-amino acid derivatives exhibiting antibacterial activity |
| US4386103A (en) | 1981-01-30 | 1983-05-31 | Merck & Co., Inc. | Dichloroamino acid derivatives useful as potent germicidal and fungicidal agents |
| US5055492A (en) | 1985-06-14 | 1991-10-08 | Masonic Medical Research Laboratory | Method for affecting reproductive cycle of insects |
| US5096700A (en) | 1990-09-28 | 1992-03-17 | The Procter & Gamble Company | Halogenated aminohexanoates and aminobutyrates antimicrobial agents |
| DE4041703C2 (de) | 1990-12-24 | 1993-10-21 | Waldemar Dr Gottardi | Alkalimetallsalze des N-Chlortaurins in kristalliner Form, Verfahren zu deren Herstellung und deren Verwendung |
| JP3759757B2 (ja) | 1994-01-13 | 2006-03-29 | 相互薬工株式会社 | 殺菌剤 |
| US5593714A (en) * | 1994-12-06 | 1997-01-14 | Hirsch; Gerald P. | Method of pressure preservation of food products |
| US5753701A (en) | 1996-10-25 | 1998-05-19 | University Of Kentucky | N-chloro-N-methyl glucamine and N-chloro-N-methyl glucamine esters as novel safe agents for water disinfection |
| DE19712565A1 (de) | 1997-03-25 | 1998-10-01 | Thomas W Dr Stief | Arzneimittel auf der Basis eines Singulett-Sauerstoff erzeugenden Agenzes |
| DE19816102C1 (de) | 1998-04-10 | 1999-09-16 | Waldemar Gottardi | Verfahren zum Inaktivieren von Viren in Proteinlösungen, Verwendung von N-Chlortaurin in dem Verfahren sowie nach dem Verfahren hergestellte Proteinlösungen |
| CA2320556A1 (en) * | 1999-09-29 | 2001-03-29 | Queen's University At Kingston | N,n-dichlorinated omega amino acids and uses thereof |
| US20040116521A1 (en) | 2000-09-14 | 2004-06-17 | Waldemar Gottardi | Fungicidal agent containing n-chlorotaurine and use thereof |
| FR2819723B1 (fr) | 2001-01-23 | 2006-11-17 | Arnaud Mainnemare | Composition halogene, son procede de preparation et ses utilisations |
| BRPI0413660A (pt) | 2003-08-18 | 2006-10-24 | Novacal Pharmaceuticals Inc | Aminoácidos n,n-di-alogenado e derivados |
| WO2005061468A1 (en) | 2003-12-17 | 2005-07-07 | Rib-X Pharmaceuticals, Inc. | Halogenated biaryl heterocyclic compounds and methods of making and using the same |
| TWI386201B (zh) | 2005-01-25 | 2013-02-21 | Novabay Pharmaceuticals Inc | Ｎ-鹵化胺基酸、ｎ，ｎ-二鹵化胺基酸與其衍生物；以及使用其之組合物與方法 |
| TW200843787A (en) | 2006-12-29 | 2008-11-16 | Novabay Pharmaceuticals Inc | N-halogenated amino compounds and derivatives; compositions and methods of using them |
-
2004
- 2004-08-17 BR BRPI0413660-8A patent/BRPI0413660A/pt not_active Application Discontinuation
- 2004-08-17 DK DK04801985.5T patent/DK1656095T3/da active
- 2004-08-17 WO PCT/US2004/026603 patent/WO2005020896A2/en active Application Filing
- 2004-08-17 EP EP13189882.7A patent/EP2725008A1/en not_active Withdrawn
- 2004-08-17 PT PT48019855T patent/PT1656095E/pt unknown
- 2004-08-17 AU AU2004268546A patent/AU2004268546B2/en not_active Ceased
- 2004-08-17 EP EP04801985.5A patent/EP1656095B1/en active Active
- 2004-08-17 SG SG200809398-1A patent/SG149043A1/en unknown
- 2004-08-17 US US10/920,636 patent/US7462361B2/en active Active
- 2004-08-17 CN CN2004800276919A patent/CN1902158B/zh active Active
- 2004-08-17 NZ NZ545654A patent/NZ545654A/en not_active IP Right Cessation
- 2004-08-17 CA CA2535926A patent/CA2535926C/en not_active Expired - Fee Related
- 2004-08-17 JP JP2006523970A patent/JP4994033B2/ja not_active Expired - Fee Related
- 2004-08-17 ES ES04801985.5T patent/ES2444845T3/es active Active
- 2004-08-17 KR KR1020067003300A patent/KR101057609B1/ko active IP Right Grant
- 2004-08-17 MX MXPA06001898A patent/MXPA06001898A/es active IP Right Grant
- 2004-08-17 SI SI200432128T patent/SI1656095T1/sl unknown
- 2004-08-17 PL PL04801985T patent/PL1656095T3/pl unknown
- 2004-08-18 TW TW093124772A patent/TWI376364B/zh not_active IP Right Cessation
- 2004-08-18 AR ARP040102965A patent/AR047757A1/es unknown
-
2006
- 2006-02-14 IL IL173726A patent/IL173726A/en not_active IP Right Cessation
-
2007
- 2007-07-20 HK HK07107842.8A patent/HK1103713A1/xx unknown
-
2008
- 2008-09-11 US US12/209,002 patent/US7893109B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1656095T3 (da) | N,n-dihalogengenerede aminosyrer og derivater | |
| EP1896001B1 (en) | N-halogenated amino acids and n, n-dihalogenated amino acids in combination with hypohalous acids | |
| WO2015153258A1 (en) | Stable compositions of uncomplexed iodine and methods of use | |
| TW200843787A (en) | N-halogenated amino compounds and derivatives; compositions and methods of using them | |
| WO2023019033A1 (en) | High molecular iodine concentration compositions, pharmaceutical formulations, preparation and uses | |
| Sadiq et al. | Pharmaceutical Importance of Anti-Microbials | |
| CN114269159A (zh) | 用于防止微生物生长的组合物、试剂盒、方法和用途 | |
| RU2008128350A (ru) | Производные дифенилмочевины | |
| RU2243152C2 (ru) | Способ получения комплекса гексафторида ксенона с трифторидом бора и его использование | |
| RU2232711C1 (ru) | Способ получения дифторида ксенона, способ его очистки от взрывоопасных примесей и его использование | |
| CN115397241A (zh) | 用于清洁、消毒、灭菌和/或治疗的组合物、试剂盒、方法和用途 | |
| RU2476241C1 (ru) | Дезинфицирующее антисептическое средство |